Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | PLK1 | P53350 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 5/20 | 0.56 |
| ▸ | TNFSF11 | O14788 | 4/20 | 0.53 |
| ▸ | HTR6 | P50406 | 6/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949716 | 0.85 | LMNA (1.00) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL30393652 | 0.85 | LMNA (1.00) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL948989 | 0.82 | AKR1C3 (0.83) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL6977875 | 0.81 | SMN1; SMN2 (0.64) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL6977871 | 0.81 | SMN1; SMN2 (0.64) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL4926276 | 0.79 | LMNA (0.74) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL8998784 | 0.79 | LMNA (0.74) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL12748630 | 0.78 | AKR1C3 (0.78) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL2886421 | 0.78 | KMT2A (1.00) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL8999130 | 0.78 | PLK1 (1.00) | LMNASMN1; SMN2PLK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533949-B2 | Processes for the preparation of 3-alkyl indoles | APOTEX PHARMACHEM INC. (CA) | 2017-01-03 | — | — | US | disclosed |
| US-20150252000-A1 | PROCESSES FOR THE PREPARATION OF 3-ALKYL INDOLES | APOTEX INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2014040164-A1 | PROCESSES FOR THE PREPARATION OF 3-ALKYL INDOLES | APOTEX PHARMACHEM INC. (CA) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252000-A1 | PROCESSES FOR THE PREPARATION OF 3-ALKYL INDOLES | GALR3, GALR2, GALR1 | LMNA 425/4885SMN1; SMN2 3558/4885PLK1 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.